PharmaShots Weekly Snapshots (March 26 – March 29, 2024)
This week PharmaShots’ news was all about the updates on M&A, Pharma, Clinical Trials, Regulatory & MedTech. Check out our full report below:
Axsome Therapeutics Reports P-III Results of AXS-12 for the Treatment of Narcolepsy
Read More: Axsome Therapeutics
SELLAS Reports P-IIa Results of SLS009 for the Treatment of Acute Myeloid Leukemia (AML)
Read More: SELLAS
Novocure Reveals the P-III (METIS) Study Results of Stereotactic Radiosurgery in NSCLC Patients
Read More: Novocure
Immuneering Doses First Patient with IMM-6-415 in the P-I/IIa Clinical Evaluation for Treating Advanced Solid Tumors
Read More: Immuneering
BMS Reveals Data from the P-III (KRYSTAL-12) Trial of Krazati as a Treatment of Non-Small Cell Lung Cancer
Read More: BMS
InnoCare Doses First Patient with ICP-189 in the P-Ib Clinical Evaluation to Treat Non-Small Cell Lung Cancer
Read More: InnoCare
The US FDA Grants Approval to Johnson & Johnson’s Opsynvi (macitentan and tadalafil) for the Treatment of Pulmonary Arterial Hypertension
Read More: Johnson & Johnson
The US FDA Grants Approval to Merck’s Winrevair (sotatercept-csrk) for the Treatment of Pulmonary Arterial Hypertension (PAH)
Read More: Merck
The US FDA Grants Approval to AstraZeneca’s Ultomiris (ravulizumab-cwvz) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Read More: AstraZeneca
The MHLW Grants Approval to Takeda’s Adzynma (apadamtase alfa/cinaxadamtase alfa) for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Read More: Takeda
The NMPA Accepts HUTCHMED’s sNDA for Savolitinib to Treat NSCLC Associated with MET Exon 14 Mutations
Read More: HUTCHMED
The EC Approves Merck’s Keytruda Combined with Chemotherapy for Treating Non-Small Cell Lung Cancer
Read More: Merck
The NMPA Accepts Astellas and Pfizer’s sBLA for Enfortumab Vedotin Plus Keytruda for Treating Bladder Cancer
Read More: Astellas & Pfizer
AbbVie Acquires Landos Biopharma for an Aggregate of $212.5M
Read More: AbbVie & Landos Biopharma
Novo Nordisk Acquires Cardior Pharmaceuticals for an Aggregate of ~$1.11B
Read More: Novo Nordisk & Cardior Pharmaceuticals
Juvisé Pharmaceuticals Acquires Actelion’s Ponvory (ponesimod) for the Treatment of Multiple Sclerosis (MS)
Read More: Juvisé Pharmaceuticals & Actelion Pharmaceutical
Verge Genomics Enters into a Collaboration Agreement with Ferrer for the Development and Commercialization of VRG50635 to Treat Amyotrophic Lateral Sclerosis (ALS)
Read More: Verge Genomics & Ferrer
ABVC BioPharma and ForSeeCon Eye Corporation (FEYE) Entered into a Global Licensing Agreement for the Development and Commercialization of Various Ophthalmology Products
Read More: ABVC BioPharma & ForSeeCon Eye Corporation
Primrose Bio and Intravacc Join Forces to Develop Conjugate Vaccine
Read More: Primrose Bio & Intravacc
GenFleet and BeiGene Join Forces to Conduct P-Ib/II Study of GFH009 and Brukinsa for Treating Diffuse Large B Cell Lymphoma
Read More: GenFleet & BeiGene
Gilead Collaborates with Xilio Therapeutics to Develop XTX301 for Treating Wide Range of Cancers
Read More: Gilead & Xilio
Health Canada Grants Approval to Innodem Neuroscience’s ETNA-MS for the Treatment of Multiple Sclerosis (MS)
Read More: Innodem Neuroscience
The US FDA Approves Medtronic’s Evolut TAVR System for the Treatment of Aortic Stenosis
Read More: Medtronic
InterSystems Collaborates with ImmunoPrecise Antibodies (IPA) to Combine the Vector Capability of Their Platforms for Healthcare Applications
Read More: InterSystems & ImmunoPrecise Antibodies
Related Post:- PharmaShots Weekly Snapshots (March 18 – March 22, 2024)
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
